| Literature DB >> 35296304 |
John Bosco Kalule1, Valeria Zalwango Nakintu2, Simon Peter SSendawula2.
Abstract
BACKGROUND: Methicillin Resistant Staphylococcus aureus (MRSA) nasal carriage in domestic pigs and vervet monkeys is a risk factor for subsequent severe infections in domestic pigs and for dissemination to the human population. This study assessed nasal carriage of MRSA in domestic pigs and sympatric vervet monkeys in a rural African village during an outbreak of a virus hemorrhagic fever suspected to be contracted from wild primates. This study was conducted during the 2012 Ebola outbreak to determine nasal carriage of MRSA in free-ranging domestic pigs and sympatric freely roaming vervet monkeys using conventional methods. Staphylococcus aureus (S. aureus) isolated from the anterior nares were tested for susceptibility to commonly used antibiotics and conventional PCR was used to confirm methicillin resistance. The MRSA strains were then genotyped using SCCmec typing.Entities:
Keywords: Antimicrobial resistance; Environment; S. aureus
Mesh:
Substances:
Year: 2022 PMID: 35296304 PMCID: PMC8925073 DOI: 10.1186/s12917-022-03212-9
Source DB: PubMed Journal: BMC Vet Res ISSN: 1746-6148 Impact factor: 2.741
Percentage resistant for isolates from free ranging domestic pigs and wild vervet monkeys
| Antibiotic (µg) | Domestic pigs (%R, | Vervet Monkeys (%R, |
|---|---|---|
| Penicillin G (10U) | 83%, 58/70 | 67%, 10/15 |
| Oxacillin (1 µg) | 11.4%, 8/70 | 26.7%, 4/15 |
| Cefoxitin (30 µg) | 11.4%, 8/70 | 26.7%, 4/15 |
| Erythromycin (15 µg) | 1.4%, 1/70 | 0.00%, 0/15 |
| Clindamycin (2 µg) | 1.4%, 1/70 | 0.00%,0/15 |
| Gentamicin (10 µg) | 1.4%, 1/70 | 0.00%, 0/15 |
| Trimethoprim/ Sulfamethoxazole (25 µg) | 90%, 63/70 | 67%, 10/15 |
| Tetracycline (30 µg) | 90%, 63/70 | 67%, 10/15 |
| Chloramphenicol (30 µg) | 1.4%, 1/70 | 0.00%, 0/15 |
| Ciprofloxacin (5 µg) | 1.4%, 1/70 | 0.00%, 0/15 |
| Fusidic acid (10 µg) | 0.00%, 0/70 | 0.00%, 0/15 |
| Rifampicin (30 µg) | 2.9%, 2/70 | 6.7%, 1/15 |
| Linezolid (30 µg) | 2.9%, 2/70 | 0.00%, 0/15 |
| Tigecycline (15 µg) | 0.00%, 0/70 | 0.00%, 0/15 |
| aVancomycin | 0.00%, 0/70 | 0.00%, 0/15 |
asusceptibility/resistance to vancomycin was based on VITEK 2
Fig. 1Characterization of the SCCmec types of methicillin resistant S. aureus (MRSA) control strains and the 12 MRSA strains. Lanes 2–14 contain MRSA strains from vervets and free-ranging pigs (lane 9 is a negative control). Lanes 16–21 contain MRSA control strains carrying SCCmec types I-VI; lane 16, COL (type I [1B]), lane 17, BK2464 (type II [2A]), lane 18, ANS46 (type III [3A]), lane 19, MW2 (type IV [2B]), lane 20, WIS (Type V [5C]) and lane 21, HDE288 (type VI [4B]). Lane 9 contains a non-template negative control, lanes 1 and 15 contain GeneRuler™ DNA molecular weight ladder (ThermoFisher Scientific Inc., MA, USA). Samples 2–8, and 11–14 amplified similar banding patterns as the control strain COL (162 bp, 342 bp, and 495 bp), Sample 10 (from vervet monkeys) amplified two bands (162 bp (mecA) and 209 bp (mecI))
Fig. 2Study Area in Luwero district, Kakute village, Uganda. The blue pointer indicates the location of Kakute village in Luwero district, Uganda. The map was drawn using ArcGIS version 10.8, (https://learngis2.maps.arcgis.com)
Primers used to amplify the mecA gene
| Primers 5’ – 3’ | 5’ – 3’ primer sequence | Amplicon size |
|---|---|---|
| TCCAGATTACAACTTCACCAGG | 162 bp | |
| CCACTTCATATCTTGTAACG |